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Introduction: Data on long term function of the Melody valve are scarce.
Patients and methods: single institution; results of percutaneous pulmonary valve implantation (PPVI) from
2006 to 2014. The function of the valved conduit was analyzed by Doppler echocardiography. Annual Chest X-
ray after implant and permanent screening for events (e.g. Endocarditis).
Results: 112 Melody valves were implanted in 111 patients; mean age 19.3 years (4.5–81.6). No pre-stenting
of the RVOT was performed (n = 4) at ﬁrst. In the next 107 patients pre-stenting was always performed. In 82
patients 1 pre-stent, 18 patients 2, in 6 patients 3 stents and 1 patient 4 stents were used. The Melody stent
was dilated up to 24 mm (n = 4), 22 mm (n = 72), 20 mm (n = 28) and 18 mm (n = 6). When stenotic, the
Doppler gradient reduced from 67.0 mm Hg (SD 13.9) to 18.9 mm Hg (SD 10.4) (p b 0.001); pulmonary
regurgitation (PR) was reduced from median 3.5/4 (range 0–4/4) to none or trivial (p b 0.001). There was no
signiﬁcant change in RVOT peak velocity at 5 years (p = 0.122) nor PR (p = 0.835). Type 1 stent fractures
were observed in 1/4 non-pre-stented patients and in 5/107 pre-stented (p b 0.05).
Endocarditis occurred in 8/112 valves; freedom of endocarditis was 85% at 5 years. In 2 patients early surgical
replacement was necessary. Six were sterilized with antibiotic treatment; 2 patients required re-stenting and
re-PPVI due to residual gradient.
Conclusion: Adequate pre-stenting of the RVOT before PPVI nearly abolishes or delays stent fracture. Cusp
function is well preserved in mid-term follow-up; endocarditis is a threat.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Percutaneous pulmonary valve implantation (PPVI) haswidely been
used throughout the world with broadening indications [1,2]. The tech-
nique has been applied in over 7000 patients with good clinical and
functional results, a very low mortality and a decreasing incidence of
complications such as mediastinal bleeding after tearing the RVOT or
conduit rupture, coronary artery occlusion due to coronary compression
or elongation, perforation or exclusion of a pulmonary artery, disloca-
tion or embolization of the valved stent, and tearing chordae of the tri-
cuspid valve [3–6]. In experienced hands the implantation procedure
has become safe and predictable with good results in early follow-up.
However, in order to determine the place of PPVI between the different
treatment strategies, long term follow-up data must be available.
This is important as PPVI must be compared with surgical series, anduisberg, Herestraat 49, B-3000
81.
lig).
d Ltd. This is an open access article unindications for PPVI are expected to shift from “symptomatic and
curative” to “prognostic and preventive”. This study provides an interim
analysis of PPVI with Melody valves in our center.
2. Patients and methods
This is a single institution interim analysis of an observational ongo-
ing study of PPVI implants; our center drains patients with congenital
heart disease of a population of about 4 million people. Since 2006 per-
cutaneous pulmonary valve replacement is performed in our center
with the Melody® valve (Medtronic Inc. Minneapolis, MN, USA). The
Melody valve consists of a balloon-expandable Cheatham-Platinum CP
stent frame (NuMED®, Hopkinton, NY, USA) with a trimmed bovine
jugular valved vein sutured at the inside (Contegra®, Medtronic Inc.
Minneapolis, MN, USA) [1–7]. The implantations were performed as
previously described [8]. All implantswere doneunder general anesthe-
sia and prophylactic antibiotic treatment (before, 6 and 18 h after proce-
dure). Access was either through the femoral or jugular vein. In all
but the ﬁrst 12 patients, balloon interrogation of the RVOT withder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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to stent implantation. In stenotic or calciﬁed conduits a high pressure
balloon was used (Mullins, NuMED, USA or Atlas Gold, Bard PV, US),
in conduit free outﬂow tracts a semi-compliable low pressure balloon
(Tyshak, NuMED, US) was used [8]. After discharge no medication was
prescribed to the patients, speciﬁcally no anti-aggregation medication.
Endocarditis profylaxis was recommended in all patients. As requested
by the Belgian health insurance for this new technique, all patients are
in strict follow-up after implantation. A clinical evaluation and an echo-
cardiography is performed 1 month, 3, 6 and 12months after valve im-
plantation and thereafter on yearly base. Chest X-ray is performed at 6
and 12 months and thereafter annually to look for recompression or
stent fractures. The databasewas screened for the event of endocarditis.
Cusp dysfunction was assessed by means of transthoracic echocardiog-
raphy based on gradient across the valve and regurgitation. All patient
datawas collected in a dedicated registry. Informed consentwas obtain-
ed in all patients by either themselves or by their parents or legal guard-
ian. Approval by the local ethics committee was granted prior to the
start of the study.
2.1. Statistical analysis
For the statistical analysis SPSS version 20 (IBM) was used. Continu-
ous data are expressed as mean and standard deviation or median and
range. Proportions and frequencies are expressed in percentage. Paired
datawere analyzed by a paired t-test and KruskalWallis test. For surviv-
al analysis Kaplan Meier plots were used. Statistical signiﬁcance was
reached when the p-value was b0.05.
3. Results
A total of 112 Melody valves were implanted in 111 patients be-
tween 2006 and 2014; mean age 19.3 years (range 4.5–81.6 years); 1
valve was explanted immediately because of coronary compression;
the median follow-up in the remaining 111 valves was 2.4 years
(range 31 days–6.9 years). The diagnosis was tetralogy of Fallot (n =
63, 56.3%), common arterial trunc (n = 7, 6.3%), status post Ross oper-
ation (n = 22, 19.6%), pulmonary atresia (n = 4, 3.6%), after Rastelli
type repair (n = 11, 9.8%) and pulmonary stenosis (n = 4, 3.6%). The
target zone consisted of a homograft in 63 patients (56.2%), a Contegra®
graft (Medtronic) in 14 patients (12.5%), after a transannular patch in 29
patients (25.9%), native pulmonary valve in 4 patients (3.6%) and 2 had
a Freestyle® graft (Medtronic) (1.7%). In the ﬁrst 4 patients no pre-
stenting of the RVOT was performed as recommended by the company
and by the product label. In the next 108 implants pre-stentingwas per-
formed prior to or at the time of PPVI (off label use for all stents). A total
of 140 pre-stents were implanted. During the time period, pre-stenting
evolved signiﬁcantly. As our experience grew, stents were implanted
until the outﬂow tract became a rigid non-restrictive tubewithout rela-
tive motion or wringing. Initially, the outﬂow tract was dilated up till
the nominal value of the surgical conduit; later all conduits were ex-
panded up to 22 to 24mmbefore deployment of theMelody valve, pro-
vided pulmonary trunc size and coronary proximity would allow so. In
patients without a previous surgical conduit (typically after a
transannular patch), initially no stent (n = 1) but thereafter a single
open cell bare stent (Andrastent XXL® Andramed, Reutlingen,
Germany) was used to provide an adequate landing zone (n =32):
we preferred a bare open cell stent to maximize grip of the stent onto
the non-stenotic outﬂow tract. If the stent was felt to be insufﬁciently
stable to withstand immediately the manipulations involved with the
Melody implantation (n = 24), the stent was left for 2 months to
allow adequate ingrowth [8]. In 3 such pre-stented patients the diame-
ter of the landing zone was ﬁrst reduced with a CP stent to about 24–
25mmprior toMelody implantation. In patients with a surgical conduit
(n = 78), no pre-stent was used in the ﬁrst 3 patients, but thereafter 1
stent was used for pre-stenting in 53 patients, 2 stents in 15 patients, 3stents in 6 patients and in one patient up to 4 stents were implanted
prior to the implantation of the valved stent. When a conduit fracture
or tear was expected (calciﬁed conduit, expansion beyond nominal
size, pressure resistant lesion), long covered CP stents (up to 65 mm)
were used to cover the target area from before the proximal anastomo-
sis until beyond the distal anastomosis.
Overall different types of stents were used: covered (n = 61) and
bare (n = 6) Cheatham Platinum (CP)® stents (NUMED, Hopkinton
NY, US), Andrastent XXL® (n = 51) (Andramed, Reutlingen,
Germany), Max LD Intrastent® (n = 17) (eV3 Europe, Paris, France),
Palmaz Genesis® (n = 5) (Cordis, Johnson & Johnson Interventional
Systems Co., Warren, NJ) (off label use for all stents). The valved stent
was dilated up to 24 mm in 4 patients, to 22 mm in 74 patients, to
20 mm in 28 patients and in 6 younger children only up to 18 mm.
3.1. Procedural complications
Some major complications occurred early in the series before 2008,
when experience of deploying large stents in the RVOT was limited. In
patient no. 3 the pulmonary artery was perforated by the Ensemble de-
livery system, this was closed surgically. In patient no. 9 coronary com-
pression occurred during PPVI with need for urgent surgical removal of
the stent. Conduit rupture with extravasation occurred in patient no. 12
who was referred to surgery to control the bleeding; the ruptured
homograft was oversewn and the Melody valve implanted by a
transventricular approach. Conduit tears with mild and contained ex-
travasation was observed in 3 patients during balloon interrogation or
pre-stenting; the tear was excluded with a covered stent in 1 patient,
and with the Melody valve in both other patients. All these complica-
tions weremanagedwithout signiﬁcant residual problem, except in pa-
tient 9 where mild left ventricular septal dysfunction persisted. With
added experience the technique evolvedwith respect to systematic bal-
loon interrogation of the RVOT,minimizing the possibility of tearing the
tricuspid chordae and coronary compression, usage of adapted guiding
wires, better control of big sheaths and guide wires during positioning
of the stents, preventive usage of long covered stents. Nomajor compli-
cation occurred after 2008.
3.2. Hemodynamic result
In 49 (44.2%) patients PPVI was performed for predominantly RVOT
obstruction (Doppler gradient N 50 mm Hg), 36 (32.4%) patients had
important pulmonary valve regurgitation (PR N 3–4/4), and in 26
(23.4%) patients a mixed type of PS and PR was the indication for
PPVI. Echocardiographic data are presented in Table 1.
The homografts (n= 63) measured at implantation 20.9 ± 2.9 mm
(range 12–27 mm) but had shrunken down to 16.6 ± 2.8 mm (10–
21 mm); after Melody implantation the lumen was expanded up to
21.3 ± 1.5 mm (range 18–24 mm) (p b 0.01); the homograft was aug-
mented 0.42±2.7mm(range−4 to+10mm) from implantation until
post-Melody (p = 0.14). Similarly the Contegra® grafts (n = 14)
measured 19.8 ± 3.6 mm at implantation (range 12–22 mm), and the
lumen was expanded from 15.7 ± 3.5 mm (range 10–22 mm) up to
21.7 ± 1.0 mm (range 20–24 mm) (p b 0.001); the Contegra was aug-
mented 1.9 ± 3.5 mm (range −2 to +10 mm) from implantation
until post-Melody (p = 0.51).
In patients with a signiﬁcant stenosis, the Doppler gradient across
the RVOT signiﬁcantly decreased from mean 67.0 ± 13.9 mm Hg to
18.9 ± 10.4 mm Hg (p b 0.001). During follow-up, no signiﬁcant in-
crease of RVOT gradient was observed at 3 years (26.7 ± 13.7 mm Hg,
p = 0.330) and at 5 years (30.7 ± 8.6 mm Hg, p = 0.220) (Fig. 1).
Pulmonary regurgitation was signiﬁcantly reduced in all patients
from median 3.5/4 (range 0–4/4) to none or trivial (p b 0.001). Pulmo-
nary regurgitation showed no signiﬁcant change at 3 years (0.5/4, range








SD p-Valuesb 3 years after
implant
SD p-Valueb 5 years after
implant
SD p-Valueb
Stenosis PS n = 48 Mean Mean Mean Mean
RVOT gradient (mm Hg) 67.0 13.9 18.9 10.4 b0.001 27.4 13.0 0.330 30.6 9.6 0.220
RVOT Vmax (cm/s) 3.5 0.7 1.7 0.85 b0.001 2.5 0.5 0.163 2.7 0.4 0.122
Regurgitation PR n = 36
Median Range Median Range Median Range Median Range
PR (grade at 4) 3.5 0–4 0.25 0–1 b0.001 0.5 0–1 0.729 0.5 0–2 0.835
Mixed PS and PR n = 26
Mean Mean Mean Mean
RVOT gradient (mm Hg) 52.5 11.1 20.9 8.5 b0.001 31.3 19.9 0.824 38.0 18 0.689
RVOT Vmax (cm/s) 3.3 0.9 2.0 0.75 b0.001 2.6 0.9 0.103 3.0 0.9 0.417
Median Range Median Range Median Range Median Range
PR (grade at 4)a 2 0–3 0 0–2 b0.001 1 0–1 0.979 1 0–1 0.505
a Pulmonary regurgitation is expressed in grade: 0 = none, 1 = slight, 2 = mild, 3 = moderate and 4 = severe.
b Statistical difference with baseline condition (before implant).
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Three patients died during follow-up, all for Melody unrelated rea-
sons (ventricular arrhythmia previously existent from a dysfunctional
left ventricle, convulsions, old age 85 years with primary diagnosis of
critical pulmonary stenosis); for all survival analyses they are with-
drawn non-censored. Freedom from valve related re-intervention was
96% 3 years after implant and 89% 5 years after implant (Fig. 3).Fig. 1. Evolution of peak Doppler RVOT gradient expressed inmmHg before, immediately
after implant and during follow-up. Indication for PPVI: (blue) pulmonary stenosis,
(green) pulmonary regurgitation, (brown)mixed PS/PR and (purple) overall the 3 groups.
Error bars express the 95% conﬁdence interval. Valves at risk: pre: 112; post 111; 1 year:
90; 3 years: 36; 5 years: 10.3.4. Stent explantation
Four valved stents were explanted after successful implantation. In 2
patients the Melody valve was implanted in a restrictive tube; because
of a persisting gradient across the RVOT and inability to dilate, the
RVOT was reconstructed with a homograft after respectively 45 and
47 months. Two Melody stents were resected in the acute phase of
endocarditis at 16 and 38 months after implantation.Fig. 2. Evolution of pulmonary regurgitation before, immediately after implant and during
follow-up. Indication for PPVI: (blue) pulmonary stenosis, (green) pulmonary regurgita-
tion, (brown) mixed PS/PR and (purple) overall the 3 groups. Error Bars express the 95%
conﬁdence interval. Valves at risk: pre: 112; post 111; 1 year: 90; 3 years: 36; 5 years: 10.
Fig. 3. Kaplan Meier survival analysis free from re-intervention. The green line shows
the valve related freedom from re-intervention, the blue line is the overall freedom from
re-intervention including e.g. balloon dilation for somatic growth. Valves at risk: time 0:
112; 2 years: 55; 4 years: 20; 6 years: 8. Fig. 4. Kaplan Meier survival free from stent fractures. The indication for PPVI was (blue)
pulmonary stenosis, (green) pulmonary regurgitation, (brown) mixed PS/PR and ](pur-
ple) overall the 3 groups. Log rank p = 0.910. Valves at risk: time 0: 112; 2 years: 57;
4 years: 18; 6 years: 9.
Fig. 5. Kaplan Meier survival free from endocarditis. Valves at risk: time 0: 112; 2 years:
59; 4 years: 26; 6 years: 11.
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Re-dilation was performed in 3 patients for somatic growth and
none for recompression. Redo PPVI was performed in a patient who
presented with progressive obstruction and at that point undiagnosed
endocarditis; he was ﬁrst treated with a bare stent to relieve the steno-
sis, and when cultures turned positive, IV antibiotics were given for
6 weeks. He received a second Melody valve 10 months later. Another
patient had a residual gradient after endocarditis; he was re-stented
2 months after the endocarditis, and a new valved stent was implanted
3months later (not included in this series). Both patients are doing clin-
ically well with now 14 and 4 months of additional follow-up.
3.6. Stent recompression or fracture
During the follow-up stent fractures were observed in 1/4 (25%) of
the non-pre-stented patients and in 5/107 (4, 6%) of the pre-stented
group (p b 0.05) (Fig. 3). Mild stent recompression was observed in 3
patients and was seen mostly at the anterior site close to the sternum,
without hemodynamic compromise in any of those patients. However,
one of these patients developed endocarditis. All observed stent frac-
tures were type I according to Nordmeyer et al., no type II or III fractures
were observed [9,10] (Fig. 4).
3.7. Endocarditis
In 8 patients endocarditiswas diagnosed based on theDuke's criteria
as “deﬁnite” in 6, and “possible” in 2, median 16.0 months after implant
(range 13.4–44.4 months). Freedom from endocarditis was 84.9% at
5 years (Fig. 5). In the patients with endocarditis the original conduit
was a homograft (n = 5), native or patch (n = 2), or a Contegra®
graft (n = 1); none of these patients had experienced endocarditis
previously. The bacteria were Corynebacterium pseudo diphtheriticum
(n = 1), HACEK (n = 3), Staphylococcus aureus (n = 1), Streptococcus
viridans (n = 2) and Streptococcus sanguinis (n = 1). The most likelypoint of bacterial entrance was the dental mucosa after inadequate or
no endocarditis prophylaxis before dental care or oral wounds in four
patients, surinfected tinea pedis in one patient and poor personal hy-
giene and nail biting in one patient; endocarditis in one patient was
classiﬁed cryptogenic.
Due to a progressive and symptomatic gradient, early explantation
of the Melody valve and surgical homograft placement were necessary
in 2 patients at 9 and 25 days after presentation. In the 6 remaining pa-
tients the conduit was sterilized with antibiotic treatment; 4 patients
had still adequate valve function (gradient b 25 mm Hg, PR b 2/4), but
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Valve replacement was therefore required in 4/8 of the cases with
endocarditis.
4. Discussion
The place of PPVI in themanagement of patientswith RVOT dysfunc-
tion still needs to be determined. Initially the Melody valve was
marketed “to extend the survival of surgical conduits”with an intended
lifetime of 2 years (label Melody). However, early results suggest that
PPVI with the Melody stent may have a more ambitious outlook. Our
study conﬁrms the good results of Melody valved stents in the right
ventricular outﬂow tract during implantation and early follow-up
[11]; moreover, good conduit function is maintained during medium
term follow-up. Good mid-term function of the Melody conduit
depends on good function of thedifferent components of theprosthesis:
the stent, the tissue conduit and the cusps.
4.1. Stent function
Stent failure may consist of recompression or fracture of the stent
wires, resulting in infolding or collapse. External forces can act on the
stent of the Melody: the valved stent frequently gets sandwiched be-
tween hard and dynamic structures as the sternum on one side and
the high pressure aorta on the other side. Calciﬁcations from previous
grafts may act as a leverage to transmit and concentrate the external
forces; the rhythmic motion of the heart beat will induce cyclic stress,
that if of sufﬁcient amplitude, will harden the metal and induce metal
fatigue, and eventually may lead to fractures after sufﬁcient cycles
[12]. Recompression or collapse of the stent with hemodynamic com-
promise in the early experience occurred as frequently as 25% after
3 years [9]. Most fractures in the reported series occurred within
6 months [3,9–14]. It was hypothesized that the effect of these forces
could be neutralized with adequate pre-stenting [10]. Pre-stenting
adds stiffness to the scaffold, thereby reducing the stress amplitude of
the metal to a level where fractures do not occur at all, or occur only
after a much larger number of cycles (Basquin law) [12]. Theoretically
pre-stentingmayhave somedisadvantages: if insufﬁcientlyﬁxed, cross-
ing strandsmay impose fretting, leverage effectmay concentrate forces,
and if different metals are used, electrolysis may occur. Lack of knowl-
edge of the latter has withheld ofﬁcial instances and companies to rec-
ommend, or even allow complex pre-stenting [10]. In this series with
pre-stenting we have observed in medium term follow-up only mini-
mal fractures, no collapse and in fewminimal recompression of theMel-
ody stent without hemodynamic compromise. There was no need for
re-stenting, nor valve-in-valve treatment [10,15]. With PPVI, gradient
relief is predominantly obtained by the pre-stenting, while the valved
stent is predominantly used to abolish the regurgitation. The use ofmul-
tiple overlapping stents and the use of simple X-ray (F & P) may have
precluded the detection of small fractures of theMelody stent; however
Doppler echocardiography excluded a clinically relevant change of
valve function, which is the ﬁnal goal of this treatment.
In 3 children a re-dilation was performed for somatic growth: a gra-
dient reoccurrence in growing children can be expected. This underlines
the value of stenting/dilating all outﬂow tracts to themaximum achiev-
able diameter at any age.
4.2. Hammock effect
Blood or tissue may accumulate around the struts of the stent be-
tween the RVOT wall and the outside of the bovine valve tissue: this
complication is no longer observed after modiﬁcation of the Melody
valve in 2003, when additional stitches were added over the full length
and circumference of the trimmedbovine venous graft onto the CP stent
[15]. The hammock complication still may occur in endocarditis wherepus and vegetations may accumulate between the stent and tissue,
which may lead to ﬂow obstruction [16,17].
4.3. Cusp failure
The cusps of the bovine jugular venous valve appear to be resistant
to wear and tear; this is the experience of the Contegra® conduit with
long lasting cusp function; the most frequent mode of Contegra® con-
duit failure is stenosis at distal anastomosis and endocarditis [18–20].
In our series with up to 7 years of follow-up, no signiﬁcant obstruction
or regurgitation at the level of the valve was observed. The pre-
stenting resulting in a large, not-restrictive conduitwith lowenergy tur-
bulence and low acceleration across the valve, may have contributed to
the longevity of the Melody cusps. This aspect needs to be evaluated
when comparing with other series.
4.4. Endocarditis
Endocarditis now appears to be the most important threat to the
Melody valve. Endocarditis of the Melody valve has been reported in
many, if not all series [14–21]. The incidence in our population was
3.0% per patient year after the ﬁrst year, which is comparable with
other reported series. Two out of 8 patients presented with a fast pro-
gressive obstruction, requiring early surgical replacement. Similar
presentations have been reported where very urgent intervention was
life-saving [1,2,17,22]. The remaining 6 patients in our series were ster-
ilized after a prolonged (6weeks) cure of IV antibiotics. In 4 patients, the
cusp function after treatment had not signiﬁcantly changed from the
pre-endocarditis evaluation. It seems that endocarditis of the Melody
valve can be cured, however with signiﬁcant morbidity (prolonged IV
antibiotics) and needs for valve replacement in many. More details re-
garding endocarditis in this patient population were recently published
[23].
Preventing endocarditis is important for long term survival of the
valved stent. In this series we did not observe reactivation of a previous
endocarditis. Endocarditis did not occur within the ﬁrst year of implan-
tation,making implantation-related infection or colonization of an early
thrombus very unlikely. No conduit is immune to endocarditis, but
some tissues may bemore vulnerable to infection. Preventive strategies
must be explored such as patient education, avoidance of entry ports for
bacteria, antibiotics in case of a predictable high level bacteremia and
avoidance of high energy turbulence by adequate pre-stenting of the
RVOT. The possible role of micro-thrombi, blood stasis in and around
the conduit, surface characteristics and cusp motion and redundancy
should be also investigated.
4.5. Comparison with surgical conduits
The valved stent compares favorably on re-intervention with other
conduits such as the homograft and Contegra conduit [18–25]. The
surgical alternative with valved conduit implantation requires longer
hospital stay, is not free of either early or late complications, and re-
quires repeated re-interventions of increasing complexity and risk. A re-
cent report from Vergales et al. shows that in the USA the total cost of
PPVI is less than surgical valve replacement and that it would require
a very dramatic short term survival of the PPVI to be less competitive;
this study reﬂects the US ﬁnancial data but cannot be extrapolated to
the European situation [26]. [27]
4.6. Limitations
Since implants only started in 2006 in our center these data reﬂect
on a limited series with medium term follow-up. Stent integrity was
assessed by chest X-ray and notwith rotational ﬂuoroscopy; this is part-
ly due to the fact that many X-rays are performed at referring centers
without access to rotational ﬂuoroscopy. We did not perform a
97B. Cools et al. / IJC Heart & Vasculature 7 (2015) 92–97controlled 2-arm study to prove the efﬁcacy of pre-stenting on the inci-
dence of stent fractures: reducing the stress amplitude by adding more
material is a basic engineering principle when avoiding metal fatigue,
and we expected objections from the ethical board against a non-
prestented study group with such expensive treatment and with
potential risk.
5. Conclusion
Adequate pre-stenting of the RVOT before percutaneous valve re-
placement offers good stent support which nearly abolishes or signiﬁ-
cantly delays stent fracture or recompression in medium term follow-
up. Cusp function is good in mid-term follow-up; its relationship with
widely opened conduits with a low gradient and turbulence needs
to be addressed. The Melody valve is vulnerable for endocarditis,
avoidance requires further research.
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